|
DE2245404C3
(de)
|
1972-09-15 |
1978-08-31 |
Robert Bosch Gmbh, 7000 Stuttgart |
Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
|
|
JPS531908B2
(enExample)
|
1973-11-12 |
1978-01-23 |
|
|
|
JPS5746634B2
(enExample)
|
1974-05-10 |
1982-10-04 |
|
|
|
JPS5146628A
(ja)
|
1974-10-17 |
1976-04-21 |
Nippon Denso Co |
Teikoirisupaakupuragu
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
CA2318576C
(en)
|
1997-12-01 |
2009-04-14 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
|
DE19818214A1
(de)
|
1998-04-24 |
1999-10-28 |
Bosch Gmbh Robert |
Zündkerze für eine Brennkraftmaschine
|
|
ATE401348T1
(de)
|
1999-05-27 |
2008-08-15 |
Us Gov Health & Human Serv |
Immunokonjugate mit hoher bindungsaffinität
|
|
JP4578025B2
(ja)
|
2001-07-06 |
2010-11-10 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
KR20130105885A
(ko)
|
2005-01-05 |
2013-09-26 |
에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. |
상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
|
|
EP2399935A3
(en)
|
2005-02-15 |
2012-02-22 |
GTC Biotherapeutics, Inc. |
An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
|
EP1861425B1
(en)
|
2005-03-10 |
2012-05-16 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
GB0624500D0
(en)
*
|
2006-12-07 |
2007-01-17 |
Istituto Superiore Di Sanito |
A novel passive vaccine for candida infections
|
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
|
CN104151429B
(zh)
|
2007-11-26 |
2018-07-10 |
拜耳知识产权有限责任公司 |
抗-间皮素抗体及其用途
|
|
HUE032735T2
(en)
|
2007-12-14 |
2017-10-30 |
Bristol Myers Squibb Co |
Binding molecules for the human OX40 receptor
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP2358390A1
(en)
|
2008-11-13 |
2011-08-24 |
Emergent Product Development Seattle, LLC |
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
AU2010230063B2
(en)
|
2009-03-24 |
2015-06-25 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
EP2407487A1
(en)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Multispecific modular antibody
|
|
CN103221428B
(zh)
|
2010-09-09 |
2016-02-10 |
辉瑞公司 |
4-1bb结合分子
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
EP2546268A1
(en)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalising immunoglobulin
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
JP5276742B1
(ja)
|
2012-08-09 |
2013-08-28 |
日本特殊陶業株式会社 |
点火プラグ
|
|
JP6307085B2
(ja)
|
2012-09-27 |
2018-04-04 |
ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ |
メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
|
|
WO2014089113A1
(en)
|
2012-12-03 |
2014-06-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
HRP20201113T1
(hr)
|
2013-03-15 |
2020-10-30 |
Glaxosmithkline Intellectual Property Development Limited |
Vežući proteini protiv lag-3
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
|
EP3686219A1
(en)
|
2014-02-04 |
2020-07-29 |
Pfizer Inc |
Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
WO2015198312A1
(en)
|
2014-06-24 |
2015-12-30 |
Ccam Therapeutics Ltd. |
Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
|
|
JP5902757B2
(ja)
|
2014-06-24 |
2016-04-13 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
BR112017002596A2
(pt)
|
2014-08-10 |
2018-01-30 |
Federal-Mogul Ignition Company |
vela de ignição com vedação melhorada
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
CA2874083C
(en)
*
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合ｃｄ１３７之抗體治療劑
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
AU2016258977C1
(en)
|
2015-05-04 |
2022-07-14 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
|
US11008396B2
(en)
|
2015-05-21 |
2021-05-18 |
Alligator Bioscience Ab |
Polypeptides
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
JP6025921B1
(ja)
|
2015-06-22 |
2016-11-16 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
KR20180029238A
(ko)
|
2015-07-15 |
2018-03-20 |
피어이스 파마슈티컬즈 게엠베하 |
Lag-3에 특이적인 신규 단백질
|
|
CA2993177A1
(en)
|
2015-07-22 |
2017-01-26 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind lag3
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
JP2018526989A
(ja)
|
2015-08-07 |
2018-09-20 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
|
|
JP6845846B6
(ja)
|
2015-09-22 |
2021-04-21 |
ディンフー バイオターゲット カンパニー リミテッド |
抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
|
|
KR101782487B1
(ko)
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
GB201519481D0
(en)
*
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
SG11201804178YA
(en)
|
2015-11-18 |
2018-06-28 |
Merck Sharp & Dohme |
Pd1 and/or lag3 binders
|
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
MX2018008308A
(es)
|
2016-01-11 |
2019-05-15 |
Inhibrx Inc |
Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
|
|
CN108602371B
(zh)
|
2016-03-18 |
2020-03-24 |
大日本印刷株式会社 |
中间转印介质、中间转印介质与热转印片的组合、以及印刷物的形成方法
|
|
RU2018139339A
(ru)
|
2016-04-22 |
2020-05-22 |
Эллигейтор Биосайенс Аб |
Новые биспецифические полипептиды против cd137
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
SG11201810591VA
(en)
|
2016-05-27 |
2018-12-28 |
Abbvie Biotherapeutics Inc |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
|
US20190106494A1
(en)
|
2016-06-13 |
2019-04-11 |
Askgene Pharma Inc. |
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
|
|
CN107523546A
(zh)
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的nk细胞及其用途
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
TW201831513A
(zh)
|
2016-06-20 |
2018-09-01 |
Ｆ星貝塔有限公司 |
結合物件(一)
|
|
EP3472207B1
(en)
|
2016-06-20 |
2021-01-20 |
F-Star Delta Limited |
Binding molecules binding pd-l1 and lag-3
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
JP2019528251A
(ja)
|
2016-07-20 |
2019-10-10 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
|
|
CN109983033B
(zh)
|
2016-09-23 |
2023-10-31 |
美勒斯公司 |
调节细胞表达的生物活性的结合分子
|
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
GB201700345D0
(en)
|
2017-01-09 |
2017-02-22 |
F-Star Beta Ltd |
Conditional agonists of immune responses
|
|
WO2018215835A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
|
US20210340250A1
(en)
|
2017-05-30 |
2021-11-04 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
WO2019025545A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
AU2018387741B2
(en)
|
2017-12-19 |
2025-09-25 |
Invox Pharma Limited |
FC binding fragments comprising a PD-L1 antigen-binding site
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
US12344672B2
(en)
|
2018-07-12 |
2025-07-01 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
SG11202112136RA
(en)
|
2019-05-14 |
2021-11-29 |
F Star Therapeutics Ltd |
Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
|